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ABSTRACT
ObjectiveToevaluatethecumulativeincidenceofcervical
intraepithelial neoplasia II or worse (grade II+) or cervical
intraepithelial neoplasia grade III+ after short term
persistence of prevalently detected carcinogenic human
papillomavirus (HPV).
Design Population based cohort study.
Setting Guanacaste, Costa Rica.
Participants 2282 sexually active women actively
followed after enrolment.
Main outcome measures Primary end points: three year
and five year cumulative incidence of histologically
confirmed cervical intraepithelial neoplasia grade II+
(n=70). Cervical specimens collected at each visit tested
for more than 40 HPV genotypes. HPV 16, 18, 26, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 were
considered the primary carcinogenic genotypes.
Results Women who tested positive for a carcinogenic
HPV at enrolment and after about one year (9-21 months)
(positive/positive) had a three year cumulative incidence
of cervical intraepithelial neoplasia grade II+ of 17.0%
(95% confidence interval 12.1% to 22.0%). Those who
tested negative/positive (3.4%, 0.1% to 6.8%), positive/
negative (1.2%, −0.2% to 2.5%), and negative/negative
(0.5%, 0.1% to 0.9%) were at a significantly lower risk.
There was little difference in the cumulative incidence of
cervical intraepithelial neoplasia grade II+ between
testing positive twice for any carcinogenic HPV genotype
(same genotype or different genotypes) v testing positive
twice for the same carcinogenic genotype (17.0% v
21.3%, respectively). Short term persistence of HPV 16
stronglypredictedcervicalintraepithelialneoplasiagrade
II+, with a three year cumulative incidence of 40.8%
(26.4% to 55.1%). Similar patterns were observed for the
five year cumulative incidence of grade II+ and for three
year and five year cumulative incidence of grade III+.
Conclusions Short term persistence of a prevalently
detected carcinogenic HPV infection, especially HPV 16,
strongly predicts a subsequent diagnosis of cervical
intraepithelial neoplasia II+ over the next few years.
INTRODUCTION
Based on the central role of persistent infections with
carcinogenic human papillomavirus (HPV) in cervical
cancer, DNA testing for carcinogenic genotypes of
HPVhasrecentlybeenintroducedintocervicalcancer
screening. HPV testing is more reliable
12 and more
sensitive but less specific than routinely performed
cytologyfordetectionofcervicalintraepithelialneopla-
sia grade III and cancer (grade III+) or grade II+.
3-7
HPV testing might soon be widely accepted as an
alternative to routine cytology for cervical cancer
screening.
8
The enthusiasm for using carcinogenic HPV testing
in primary screening, however, has been tempered by
its lower predictive value or absolute risk for cervical
intraepithelial neoplasia grade II+ or III+ after a posi-
tive result compared with abnormal cytology. Even in
older women the prevalence of self limited carcino-
genic HPV infection can reach 10%, with only a min-
ority of at risk women developing grade II+.
Some possible ways to improve the positive predic-
tivevalueafterHPVprimaryscreeninghavebeensug-
gested.Oneistousecytologyasareflextestforwomen
positive for carcinogenic HPV because definitely
abnormal cytology is more specific for cervical intra-
epithelial neoplasia grade III+.
9 Another possibility is
HPV genotyping to target the most carcinogenic gen-
otypes and permit the tracking of viral persistence.
Separate detection of HPV 16 and 18 in cytologically
normal women aged 30 and older might be useful for
identifying those at an increased risk of cervical intra-
epithelialneoplasiagradeII+.
1011Thosewhotestposi-
tive might benefit from immediate colposcopy, while
those who test negative for both could wait a year
before being screened again.
1011
GiventhefundamentalroleofpersistentHPVinfec-
tion in cervical carcinogenesis, its reliable measure-
ment could increase the accuracy of cervical cancer
screening by further distinguishing carcinogenic
HPV infections that pose the greatest risk from less
1Division of Cancer Epidemiology
and Genetics, National Cancer
Institute, National Institutes of
Health, DHHS, Bethesda, MD
20892, USA
2Division of Cancer Prevention,
National Cancer Institute, National
Institutes of Health, DHHS,
Bethesda, MD 20892, USA
3Proyecto Epidemiológico
Guanacaste, INCIEN
SA Foundation, San José,C o s t a
Rica
4Albert Einstein Cancer Center,
Albert Einstein College of
M e d i c i n e ,B r o n x ,N Y1 0 4 6 1 ,U S A
Correspondence to: P E Castle
castlep@mail.nih.gov
Cite this as: BMJ 2009;339:b2569
doi:10.1136/bmj.b2569
BMJ | ONLINE FIRST | bmj.com page 1 of 13risky infections because they have already been
clearedorsuppressedbytheimmunesystem.Carcino-
genic HPV types that are found prevalently on screen-
ing tend to clear quickly, with about 50% undetectable
within 6-12 months and most being undetectable by
two years.
1213 A recent systematic review and meta-
analysisoftheriskposedbyHPVpersistenceafterpre-
valently detected infections found that the summary
estimated relative risk for cervical precancer with per-
sistentversustransientinfectionwas14.7,increasingto
42.9 with persistence for about one year.
14 Therefore,
monitoring a prevalently detected HPV infection for a
year or more might be useful.
18 Women with one year
persistence of a specific HPV genotype remain at an
increasedriskofcervicalprecancerandcancerforsev-
eral years, even if colposcopic evaluation at time zero
initially fails to detect disease.
5
Usingdatageneratedfromapopulationbasedstudy,
we examined the possible utility of measuring viral
persistence over about a one year interval (
9-21 months) and the risk of precancer and cancer
over the subsequent years of follow-up. We examined
whether measuring short term persistence of preva-
lently detected HPV infections quantifies the risk of
cervical precancer and cancer, and whether different
test configurations—that is, measuring persistence of
a specific HPV genotype for all versus only the most
carcinogenic genotypes (HPV 16 and 18)—differenti-
atebetweenwomenatlesserandgreaterriskofcervical
precancer and cancer.
METHODS
Study population
This population based cohort study included partici-
pants from Guanacaste, Costa Rica, enrolled between
June 1993 and December 1994.
131516 After randomly
selecting about 20% of the census tracts in the region
(11742 women), 10769 were eligible for the study. Of
these, 10049 (93.3%) provided informed written con-
sent. Detailed methods of recruitment, screening, and
follow-up have been previously published.
1516 Our
cohort comprised 8545 women with baseline HPV
testing and an intact cervix (fig 1). We excluded
women who had undergone hysterectomy (n=630),
were virgins (n=583), or refused a pelvic examination
(n=291). Highly trained study nurses conducted
screening visits and collected cervical specimens.
We referredtocolposcopythose womenwho,at the
enrolment visit, had equivocal or definitely abnormal
cytology (on any of three methods), abnormal direct
visual examinations, or the appearance of cervical
abnormalities on review of their Cervigrams, a static
photographic image of the cervix. To permit indivi-
dualised care outside the study protocol, we excluded
from active follow-up 290 women who had some evi-
dence of cervical intraepithelial neoplasia grade II+ at
enrolment, whether or not this was confirmed histolo-
gically by colposcopy and directed biopsies.
Aspreviouslydescribed,
15weactivelyfollowedasub-
cohortofsexuallyactivewomen(2626/8545, 30.7%) at
intervals of six or 12 months to explore risk factors for
incident cervical intraepithelial neoplasia grade II+.
(We included 25 women who did not have a pelvic
examination at enrolment and four women who had
not yet reported becoming sexually active but were
older than 26 in the active follow-up, but we excluded
them from this analysis based on the criteria described
below.) Choice of the subcohort was based on the per-
ceivedriskofdevelopingcervicalintraepithelialneopla-
sia grade II+ according to screening results and
colposcopy; 60.0% of these 2626 women underwent
colposcopic evaluation (at a median of 95 days, mean
113 days), while others were included in the subcohort
because they had five or more lifetime sexual partners
or high viral load HPV infection as determined by an
earlyHPVassay(HCTubeTest,Digene,Gaithersburg,
MD).Arandomsampleofallwomenwithnoscreening
abnormalities and without these risk factors
15 (n=540)
was also chosen for active follow-up. Thus, this subco-
hortrepresentedamixtureofhigherriskwomen(based
on enrolment screening results and sexual behaviour)
and was supplemented by a random sample of the
remaining cohort population.
Women were initially followed annually, except for
the492withlowgradeintraepitheliallesionorcervical
intraepithelial neoplasia grade I at baseline, who were
followed at six month intervals for increased safety of
the participants. During the course of the study, as in
regular clinical practice, women were shifted to
Enumerated by census (n=11 742)
Eligible (n=10 769)
Provided informed consent (n=10 049)
Main cohort (n=8545)
Cohort with follow-up (n=8255)
Analysed (n=2282)
(1812 high risk women and 470 low risk women)
Passive cohort (n=5629) Active cohort (n=2626)
(2100 high risk women
and 526 low risk women)
Excluded (n=1504):
  Virgins (n=583)
  Refusals (n=291)
  Hysterectomies (n=630)
Censored (due to CIN II+)
(n=290)
Missing baseline or 1 year
follow-up PCR results (n=344)
Fig 1 | Flow of women through trial. High risk refers to women
with positive results on screening or with risk factors (such as
five or more lifetime sexual partners) for HPV or cervical
neoplasia. Low risk refers to women with negative results and
no risk factors. CIN= cervical intraepithelial neoplasia;
PCR=polymerase chain reaction
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sented with low grade cytological or histological
abnormalities.
HPV genotyping with polymerase chain reaction
wasperformedonstoredspecimens.Of the2626eligi-
ble actively followed women, 2282 (86.9%) attended a
one year follow-up visit (9-21 months) and had ade-
quate polymerase chain reaction results at both enrol-
ment and at their one year follow-up visit to be
included in this analysis of short term persistence.
This analysis included 1812 of 2100 of women
(86.3%)witheitherscreeningabnormalitiesorriskfac-
tors (“high risk” women) and 470 of 540 randomly
selected women (79.6%) with no screening abnormal-
ities and no risk factors (“low risk” women).
Throughout the study, women with cytological,
visual, or Cervigram evidence of high grade cervical
neoplasia were referred to colposcopy performed by
an expert colposcopist (JM). At exit, to ensure the
safety of women leaving the cohort, we referred
women with abnormal (atypical squamous cells of
uncertain significance (ASCUS) or low grade squa-
mous intraepithelial lesions (LSIL)) cytological inter-
pretation; a positive Cervigram (P0 or P1) in either of
the last two screening visits; or persistent carcinogenic
HPV infection or HPV 16 or HPV 18 at either of the
last two screening visits. Finally, a 6.25% random sam-
ple of the cohort was referred for an exit colposcopy.
Collection of specimens
Twoexfoliativecervicalspecimenswereobtaineddur-
ing a single pelvic examination at baseline and all fol-
low-up visits.
1516Thefirst specimenwas collectedwith
a Cervex cytology broom directed at the cervical os.
After preparation of conventional smears, the remain-
ingcellswereplacedintoPreservCyt(Cytyc)medium,
fromwhichthinlayercytologyslides(ThinPrep,Cytyc
Corp, Marlborough, MA) were made. A second cervi-
cal specimenwassimilarlycollectedimmediately after
thefirstbyusingaDacronswabthatwasthenstoredin
specimen transport medium (STM; Qiagen, Gaithers-
burg, MD).
HPV DNA testing
PolymerasechainreactiontestingwasdonewithDNA
prepared from the stored specimen collected at each
visit. To amplify HPV DNA, we used a MY09/M11
L1 degenerate primer polymerase chain reaction
(MY09/11 PCR) method as described previously.
17
Dot blot hybridisation of polymerase chain reaction
productsforHPVgenotypespecificdetectionwascon-
ducted with genotype specific oligonucleotide probes
for HPV genotypes 2, 6, 11, 13, 16, 18, 26, 31-35, 39,
40, 42-45, 51-9, 61, 62, 66-74, 81-85, and 89.
17 Probes
for genotypes 2, 13, 34, 42-44, 54, 57, 69, 74, and 82
were also combined in dot blot hybridisations for
detection of rare genotypes (dot blot mix). Specimens
that were HPV positive after Southern blot hybridisa-
tion with a radiolabelled generic probe mix, but were
not positive for any specific probe, were considered to
be positive for uncharacterised genotypes. For
consistency with a related analysis,
18 HPV genotypes
16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68,
73, and 82 were considered as primary carcinogens.
Finally, the HPV test results were assigned hierarchi-
cally to a HPV risk group based on the relative impor-
tance (carcinogenicity) of each genotype
1920: positive
forHPV16;positiveforHPV18butnegativeforHPV
16; positive for any carcinogenic HPV genotypes but
negative for HPV 16 and HPV 18 (carcinogenic HPV
excluding HPV 16 and HPV 18); and negative for car-
cinogenic HPV genotypes. We abbreviated this hier-
archy as HPV 16 positive >HPV 18 positive >other
carcinogenic HPV genotypes >negative.
Pathology
All women with possible cervical intraepithelial neo-
plasiagradeII+atanytime,detectedbyanyscreening
technique, and including a nurse’s concern on gross
examination, were referredto colposcopy with guided
biopsyof visiblelesionsandcensoredfromfurtherfol-
low-up. Women diagnosed locally on initial histologi-
cal evaluation as grade II+ were treated by large loop
excision or by inpatient surgeryasclinically indicated.
MES and DS reviewed histology diagnosed locally as
gradeIIorworse.Thefinalassignmentofcasesasinva-
sive cancer, grade III, grade II, or <grade II was made
according to an algorithm based on the independent
masked reviews. Occasionally a few difficult cases
were adjudicated by joint review with consideration
of cytological slides as well as histology.
Statistical methods
Weusedcervical intraepithelialneoplasiagradeII+as
ourprimaryendpointbecausegradeIIwasthethresh-
old for treatment. We also used grade III+ in some
analyses, recognising that grade II represents an equi-
vocal diagnosis of cervical precancer
2122 whereas
grade III is a more definite cervical cancer precursor
and is less likely to regress.
We were primarily interested in looking at the sim-
plecumulativeincidenceand95%confidenceintervals
of cervical intraepithelial neoplasia II+ or III+ (see
appendix on bmj.com for further details of the statisti-
calanalysis)fordifferentcombinationsoftestresultsto
simulate different possible formulations of HPV tests:
detection of any carcinogenic HPV without individual
identificationoftheHPVgenotype(HybridCapture2,
Qiagen, Gaithersburg, MD, USA; Amplicor, Roche
Diagnostics, Indianapolis, IN, USA, currently
approved for use in Europe only); partial HPV geno-
typinginwhichHPV16and18aredetectedseparately
in addition to aggregate detection of all carcinogenic
genotypes (Cervista HPV HR Molecular Assay,
Third Wave Technologies, Madison, WI, USA, cur-
rently approved for use in Europe only with HPV
16/18 Molecular Assay, research use only); and full
individual HPV genotyping for all carcinogenic HPV
genotypes (Linear Array, Roche Molecular Systems,
Alameda,CA,USA,currentlyapprovedforuseinEur-
opeonly).Wecombinedtestresultsforindividualgen-
otypes to simulate pools of genotypes. Results were
RESEARCH
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persistence as the top category, such that women who
hadpersistenceofanygenotypewereclassifiedashav-
ing persistence regardless of whether other genotypes
were present at either time point. We also calculated
cumulative incidence rate ratios with 95% confidence
intervals for cervical intraepithelial neoplasia grade II
+ end points by using women who tested positive for
carcinogenic HPV at enrolment and negative at the
follow-up visit as the reference group because we
were interested in differentiating between low risk
and high risk women who tested positive for carcino-
genic HPV at enrolment. We used simple cumulative
incidence curves, rather than more complex model-
ling,todescribethedatabecausetherewasnoappreci-
abledifferencebyHPVstatusinthenumberofwomen
who underwent censoring treatment or an exit visit
(90-95%) (data not shown) and most women attended
their annual visits (80%-90% per visit), with only small
differences in attendance by HPV status.
We examined patternsof cumulativeincidence stra-
tified by age (<30 and ≥30). We also evaluated the
impact of having a colposcopic evaluation during the
enrolment period or as the result of the six month fol-
low-up visit for 492 women with low grade squamous
intraepithelial lesions or cervical intraepithelial neo-
plasia grade I; 11 (2.2%) women seen at the six
monthfollow-upwerecensoredforcervicalabnormal-
ities and excluded from this analysis. Finally, we eval-
uated by stratification the impact of having non-
normal cytology (atypical squamous cells of undeter-
mined significance or more severe) versus negative
cytology at the 9-21 month follow-up visit.
RESULTS
Table 1 shows the basic enrolment demographics of
thesubcohortof2282womenincludedinthisanalysis.
The median age was 37.0 years (mean 40.1, range 18-
91). Most women were current (21.9%) or former
(43.1%) users of oral contraceptives, were married
(77.2%), and had had at least one previous smear test
(89.7%) at the time of enrolment, although the accu-
racy of that screening was typically not optimal.
16 Of
the 2282 women, 542 (23.8%) tested positive for carci-
nogenic HPV at enrolment.
As we have previously reported,
18 more than half
(282, 52.0%) of the 542 women who were positive for
one or more carcinogenic HPV genotypes at enrol-
ment cleared their infection(s) after a year. Among
the 209 (38.6% of the 542) women with at least short
term persistent carcinogenic HPV infection, 55
(26.3%) had persistent HPV 16, 18 (8.6%) had persis-
tent HPV 18, and the 136 remaining (65.1%) had gen-
otype specific persistence for other carcinogenic
genotypes. Twenty five of 209 (12.0%) women had
more than one persistent carcinogenic HPV infection
for one year or more.
Table 2 shows the numbers of women by HPV sta-
tus and disease outcome (cervical intraepithelial neo-
plasia grade II+). Forty six of the 260 women (17.7%)
who tested repeatedly positive for carcinogenic HPV
were diagnosed with grade II+ during follow-up. By
comparison, 4.8% (n=6) of women who were negative
and then positive for carcinogenic HPV, 1.8% (n=5) of
womenwhowerepositiveandthennegative,and0.8%
(n=13) of women who tested negative twice were diag-
nosed with grade II+ during follow-up. There were no
appreciable differences in the percentage of women
with grade II+ for a given HPV status between high
risk and low risk women, only differences in the distri-
bution of women with a given HPV status (P<0.001).
Wethereforeconsiderthepopulationof2282inaggre-
gate in our subsequent analyses.
Table 3 shows the three year and five year cumula-
tive incidence of cervical intraepithelial neoplasia
grade II+ and grade III+ after the 9-21 month follow-
upvisit.Wefirstexaminedthecumulativeincidenceof
grade II+ for paired test results, at enrolment, and
Table 1 |Characteristics of subcohort of 2282 women
(median age 40.1)
No (%)
Oral contraceptive use:
Data missing 1 (0.0)
Never used 798 (35.0)
Former user 983 (43.1)
Current user 500 (21.9)
Barrier contraceptive use:
Data missing 1 (0.0)
Never used 1278 (56.0)
Former user 770 (33.7)
Current user 233 (10.2)
No of live births
0 127 (5.6)
1-2 757 (33.2)
3-4 630 (27.6)
≥5 768 (33.7)
Marital status:
Married 1762 (77.2)
Separate/divorced 132 (5.8)
Widowed 85 (3.7)
Single 303 (13.3)
Cervical smear before enrolment:
Yes 2047 (89.7)
No 233 (10.2)
Do not know 2 (0.1)
Abnormal smear result before enrolment:
Yes 524 (23.0)
No 1523 (66.7)
Never had one/do not know 235 (10.3)
HPV status at 1 year:
Persistent HPV 16 55 (2.4)
Persistent HPV 18 18 (0.8)
Persistent for specific carcinogenic
genotype (not HPV 16/18)
136 (6.0)
Persistent for carcinogenic HPV
(not specific genotype)
51 (2.2)
Acquired carcinogenic HPV 125 (5.5)
Cleared carcinogenic HPV 282 (12.4)
Negative (and negative at baseline) 1615 (70.8)
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The three year cumulative incidence of grade II+ was
17.0% (95% confidence interval 12.1% to 22.0%) for
women who tested positive for carcinogenic HPV
twice (positive/positive), regardless of whether they
were the same carcinogenic types (table 3, fig 2). The
three year cumulative incidence of cervical intra-
epithelialneoplasiagradeII+foreachoftheothercom-
binations of test results was 3.4% (0.1% to 6.8%) for
negative/positive (acquired), 1.2% (−0.2% to 2.5%) for
positive/negative(cleared),and0.5%(0.1%to0.9%)for
negative/negative. The five year cumulative incidence
of grade II+ for positive/positive, negative/positive,
positive/negative, and negative/negative was 23.7%
(14.8% to 32.6%), 4.4% (−0.3% to 5.1%), 1.6 (0.04% to
3.1%), and 0.5% (0.1% to 0.9%), respectively. We
observed no appreciable differences in the cumulative
incidenceofgradeII+whenwestratifiedbythemedian
time interval (≤408 v >408 days) between the enrol-
ment and follow-up visits (for example, the three year
cumulative incidence of grade II+ for women testing
positive for carcinogenic HPV twice in ≤408 and >
408 days was 16.90% (9.91% to 23.89%) and 17.21%
(10.07% to 24.34%) (data not shown).
Table 2 |HPV status and outcomes for 2282 women included in analysis
HPV status
All women High risk women* Low risk women†
No of women
No (%)
with CIN II+ No of women
No (%)
with CIN II+ No of women
No (%)
with CIN II+
Repeatedly positive for carcinogenic HPV (Pos/Pos):
Total 260 46 (17.7) 246 44 (17.9) 14 2 (14.3)
HPV 16 persistence 55 20 (36.4) 52 19 (36.5) 3 1 (33.3)
HPV 18 persistence 18 5 (27.8) 18 5 (27.8) 0 0
Type specific persistence 136 21 (15.4) 126 20 (15.9) 10 1 (10.0)
Non-specific persistence 51 0 (0.0) 50 0 (0.0) 1 0 (0.0)
Acquisition (Neg/Pos) 125 6 (4.8) 111 5 (4.5) 14 1 (7.1)
Clearance (Pos/Neg) 282 5 (1.8) 263 4 (1.5) 19 1 (5.3)
Neg/Neg 1615 13 (0.8) 1192 11 (0.9) 423 2 (0.5)
Total 2282 70 (3.1) 1812 64 (3.5) 470 6 (1.3)
*Screen positive or had risk factors (such as five or more lifetime sexual partners) for HPV or cervical neoplasia.
†Screen negative and did not have above risk factors.
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Fig 2 | Cumulative incidence of cervical intraepithelial neoplasia (CIN) grade II or worse (II+) and grade III+ after repeat
measurements of carcinogenic human papillomavirus (HPV) at about one year interval (9-21 months) in women who tested
positive for carcinogenic HPV twice (Pos/Pos), positive for carcinogenic HPV at enrolment but negative at follow-up (“cleared”),
negative for carcinogenic HPV at enrolment but positive at follow-up (“acquired”), or negative at both time points (Neg/Neg). In
right panels the Pos/Pos category is further stratified into those with at least one persistent carcinogenic HPV genotype
(persistence) v positive for different carcinogenic HPV genotypes (Pos/Pos (no persistence)), with unstratified Pos/Pos curves
shown for reference. Time 0* indicates start time of analysis, 9-21 months after enrolment
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used cervical intraepithelial neoplasia grade III+ as
the end point (table 3, fig 2). For example, the three
year cumulative incidence of grade III+ for positive/
positive, negative/positive, positive/negative, and
negative/negative was 11.3% (7.0% to 15.6%), 1.6%
(−0.6% to 38.0%), 0% (confidence interval not avail-
able), and 0.3% (0.01% to 0.6%), respectively.
Amongthosewomenwhotestedrepeatedlypositive
forcarcinogenicHPV,wewereinterestedinthecumu-
lative incidence of cervical intraepithelial neoplasia
grade II+ among all women who tested positive twice
forcarcinogenicHPVcomparedwiththesubgroupsof
women who tested positive twice for carcinogenic
HPV and had HPV genotype specific persistence and
those tested positivefor different HPV genotypes(that
is, one HPV genotype cleared and another was
acquired). In this population with median age of 40.1,
well past the peak of HPV incidence, we found that
most women repeatedly positive for carcinogenic
HPV had HPV genotype specific persistence (209/
260, 80.4%). In this small group of women who tested
positive for carcinogenic HPV at both time points but
for different genotypes, none developed ≥grade II.
Therefore,amongthosewhotestedrepeatedlypositive
forcarcinogenicHPV,allincidentgradeII+andgrade
III+ diagnoses during follow-up were linked to HPV
genotype specific persistence (table 3, fig 2).
Of the1615womenwhotestednegativeforanycar-
cinogenic HPV genotype at both time points, 104
(6.4%)hadshorttermpersistencefornon-carcinogenic
HPV(datanotshown).Onlyoneofthesewomen,how-
ever, was diagnosed as a case (cervical intraepithelial
neoplasia grade III) over the entire follow-up, yielding
a seven year risk for grade II+ and grade III+ of 1.2%
(95% confidence interval −1.1% to 3.6%), and this was
probably the result of an incident HPV 31 infection
acquired after the 9-21 month interval that persisted
almost four years before the grade III diagnosis.
We repeated our analysis to examine how age (<30
(n=612, median age 25) v ≥30 years (n=1670, median
age 42) modified these patterns (table 4). The three
year and five year cumulative incidence of cervical
intraepithelial neoplasia grade II+ for women <30
was 19.0% (8.3% to 24.3%) and 20.3% (11.5% to
29.0%), respectively. For women ≥30 years the inci-
dence was 15.8% (9.7% to 21.9%) and 25.9% (12.6%
to 39.2%), respectively. Cumulative incidences after
other detection patterns (acquisition, clearance) were
much lower than in women repeatedly testing positive
for carcinogenic HPV.
Among women with persistently positive results for
carcinogenic HPV, a greater proportion of those aged
≥30 (143/163,87.7%) had persistence of specific geno-
types (v different genotypes) than those aged <30 (66/
97, 68.0%) (P<0.001, Fisher’s exact) (table 4). Thus,
there was qualitatively a greater difference in the
cumulative incidence of cervical intraepithelial neo-
plasia grade II+ among all women who tested repeat-
edly positive for carcinogenic HPV from the subset of
women persistently positive for specific HPV geno-
typesaged<30thaninthoseaged≥30.Wefoundsimi-
lar patterns in cumulative incidence, with wider
confidence intervals because of smaller numbers, for
grade III+ (data not shown).
We also considered separate detection of HPV 16
and HPV 18 and the risk of cervical precancer and
cancer (table 3, fig 3) after classifying our HPV test
Table 3 |Three year and 5 year cumulative incidence rates of cervical intraepithelial neoplasia grade II or more severe (CIN II+) and CIN III+ after repeat
measurements of carcinogenic human papillomavirus (HPV) at about 1 year interval (9-21 months)
No of
women
CIN II+ CIN III+
3 year 5 year 3 year 5 year
No of
cases
Rate*
(95% CI)
Rate ratio†
(95% CI)
No of
cases
Rate*
(95% CI)
Rateratio†
(95% CI)
No of
cases
Rate*
(95% CI)
No of
cases
Rate*
(95% CI)
Rate ratio†
(95% CI)
Carcinogenic HPV
persistence
260 38 17.04 (12.05
to 22.03)
14.53 (4.53
to 46.58)
42 23.69 (14.75
to 32.62)
14.99 (5.28
to 42.62)
24 11.27 (6.97
to 15.57)
28 18.38 (7.02
to 15.10)
44.66 (5.94
to 335.88)
Specific genotype
persistence
209 38 21.26 (15.18
to 27.33)
18.12 (5.66
to 57.99)
42 29.90 (18.65
to 41.14)
18.92 (6.66
to 53.76)
24 14.22 (8.86
to 19.57)
28 23.63 (11.88
to 35.57)
57.42 (7.63
to 432.02)
Non-persistence 51 0 0.00 0.00 0 0.00 0.00 0 0.00 0 0.00 0.00
HP 16 persistence 55 19 40.77 (26.40
to 55.13)
34.75 (10.66
to 113.26)
19 40.77 (26.40
to 55.13)
25.81 (9.16
to 72.71)
13 30.57 (16.42
to 44.71)
13 30.57 (16.42
to 44.71)
74.28 (9.95
to 554.32)
HPV18persistence 18 3 17.46 (−0.58
to 35.50)
14.88 (3.22
to 68.70)
31 7 . 4 6 ( −0.58
to 35.50)
11.05 (2.67
to 45.73)
15 . 5 6 ( −5.03
to 16.14)
15 . 5 6 ( −5.03
to 16.14)
13.50 (0.88
−207.03)
Carcinogenic HPV
persistence(not16
and 18)
187 16 10.00 (5.32
to 14.68)
8.53 (2.51
to 28.91)
20 18.19 (8.02
to 28.37)
11.52 (3.75
to 35.41)
10 6.23 (2.52
to 10.23)
14 14.90 (4.66
to 25.13)
36.20 (4.55
to 287.76)
Acquisition 125 4 3.44 (0.10
to 6.78)
2.93 (0.66
to 12.98)
54 . 4 4 ( −0.28
to 5.08)
2.81 (0.76
to 10.35)
21 . 6 0 ( −0.60
to 3.80)
32 . 6 3 ( −0.28
to 5.08)
6.38 (0.67
to 60.93)
Clearance
(reference)‡
282 3 1.17 (−0.15
to 2.50)
1.00 4 1.58 (0.04
to 3.12)
1.00 0 0.00 1 0.41 (−0.39
to 1.22)
1.00
HPV negative 1615 7 0.49 (0.13
to 0.85)
0.42 (0.11
to 1.61)
7 0.49 (0.13
to 0.85)
0.31 (0.09
to 1.06)
4 0.28 (0.01
to 0.56)
4 0.28 (0.01
to 0.56)
0.69 (0.08
to 6.12)
*Cumulative incidence rates.
†Cumulative incidence rate ratio; when no events of CIN II+ occurred in reference group, this could not be calculated (NA).
‡Women who tested positive and then negative for carcinogenic HPV (“clearance”).
RESEARCH
page 6 of 13 BMJ | ONLINE FIRST | bmj.comresults hierarchically according to importance in caus-
ingcancer(HPV16positive>HPV18positive>other
carcinogenic HPV genotypes >negative). The three
and five year cumulative incidence of cervical intra-
epithelial neoplasia II+ was 40.8% (26.4% to 55.1%)
after short term HPV 16 persistence (table 3, fig 3)
and 17.5% (−0.6% to 35.5%) after short term HPV 18
persistence.Repeatedlytestingpositiveforothercarci-
nogenic HPV genotypes as a pool predicted three and
five year risks for grade II+ of 10.0% (5.3% to 14.7%)
and 18.2% (8.0% to 28.4%), respectively.
Among women aged <30, short term persistence of
HPV 16 was highly predictive of a subsequent diagno-
sisofcervicalintraepithelialneoplasiagradeII+,witha
three (and five) year risk of 65.9% (40.4% to 91.5%)
(table 4, fig 3). By comparison, among women aged
≥30, the three (and five) year risk after short term
HPV 16 persistence was 27.2% (11.1% to 43.3%)
(table 4, fig 3). There was no significant difference in
the intensity of follow-up (median number of days
between visits) by HPV status, although women who
were in higher risk HPV groups (such as persistent
HPV 16) naturally had fewer follow-up visits on aver-
age because of censoring treatments for diagnoses of
grade II+ (P<0.001 for trend) (data not shown).
We compared the cumulative incidence of cervical
intraepithelial neoplasia grade II+ among all women
who tested positive twice for carcinogenic HPV geno-
types otherthan HPV 16 and 18 with the subgroupsof
women who persistently had specific HPV genotypes
and those tested positive for different HPV genotypes
(seesupplementalfigureonbmj.com).Againwefound
thatonlyasmallpercentage(51/187,27.3%)ofwomen
repeatedlypositiveforcarcinogenicHPVdidnothave
persistence of specific genotypes, although it is note-
worthythatthenumberofwomenwithoutviralpersis-
tence was the same as when we considered all
carcinogenic HPV genotypes. A greater proportion
of women aged ≥30 (99/119, 83.2%) who repeatedly
tested positive for carcinogenic HPV had persistence
ofspecificHPVgenotype(vpositivefordifferentHPV
genotypes) compared with women aged <30 (37/68,
54.4%) (P<0.001, Fisher’s exact). Consequently,
among women aged <30, the cumulative incidence of
cervicalintraepithelialneoplasiagradeII+(seesupple-
mental figure on bmj.com) among the entire group of
women who tested positive twice for carcinogenic
HPVgenotypesotherthanHPV 16and18wasalmost
half that for the subgroup of women with confirmed
viralpersistenceofspecificHPVgenotypes.Forexam-
ple, the three year cumulative incidence of grade II+
among women aged <30 was 7.1% (0.4% to 13.8%) in
those who tested positive twice for carcinogenic HPV
genotypesotherthanHPV16and18and28.8%(3.9to
212.0) in the subgroup of women with confirmed per-
sistence of specific HPV genotypes.
Wewerealsointerestedinwhetherhavingabnormal
cytology(atypicalsquamouscellsofundeterminedsig-
nificance or worse) versus normal cytology at the fol-
low-up visit modified the observed patterns of HPV
persistence and risk of cervical intraepithelial
neoplasia grade II+ or III+. As shown in table 5, the
patterns observed for other groups were qualitatively
similar except that women with atypical squamous
cells of undetermined significance or worse generally
had higher cumulative incidence of disease than those
who had normal cytology, most noticeably in the ear-
lier follow-up times.
Finally, we considered whether short term viral per-
sistencestronglypredictedcervicalintraepithelialneo-
plasia grade II+ after colposcopy (conducted during
the enrolment phase) without findings of grade II+
(table 6). We again observed a high risk of grade II+
and III+ with short term HPV viral persistence, espe-
cially for HPV 16, whether or not a woman had
recently undergone colposcopy to rule out cervical
intraepithelial neoplasia grade II+.
DISCUSSION
Testing for short term HPV persistence might be clini-
cally useful for assessing the risk of cervical intra-
epithelial neoplasia grade II+ among women who
test positive for carcinogenic HPV. We carried out
our study in a subcohort of women enrolled in our
population based cohort in Guanacaste, Costa Rica.
We focused on measurements over about one year (
9-21 months) because there was previous evidence
that measuring persistence over that duration begins
to differentiate between transient and clinically rele-
vant HPV infections.
52324 In the United States, one
year is the recommended follow-up time for women
who have an abnormal screening result but do not
have concurrent, colposcopically detected cervical
intraepithelial neoplasia grade II+.
11
Women who tested positive twice for carcinogenic
HPVhadanincreasedriskofgradeII+andIII+,while
the risk in women who test negative for carcinogenic
HPV at either or bothtime points waslow. We didnot
observe any appreciable differences in the risks
between those women with a shorter and longer time
intervals between the enrolment and follow-up visit,
suggesting that these findings are robust to variability
in which women return for follow-up testing. Among
those who tested positive twice for carcinogenic HPV,
all subsequent diagnoses of cervical intraepithelial
neoplasiagradeII+werelinkedtopersistenceofaspe-
cific HPV genotype. With the exception of HPV 16
and possibly HPV 18, however, detection of persis-
tence of a specific genotype did not differentiate
women at risk for grade II+ qualitatively better than
repeated detection of an aggregate of carcinogenic
HPV types. Few women had HPV 18 at enrolment,
which led to unstable estimates of related cumulative
incidence of grade II+. Yet, the weight of evidence
regardingtheutilityofHPV18detection,
1025including
it being the second leading cause of cancer and its
strong association with adenocarcinoma,
20 which is
on the rise in the US
26 and Europe
27 and might be
more difficult to detect by cytology based screening,
would argue in favour of its separate detection.
In summary, repeat testing (versus one time tests)
might further divide the population into low risk and
RESEARCH
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of HPV 16 and might be particularly useful to identify
women at risk for cervical precancer.
Previous studies
Previousstudiesthatlookedatrepeattestingwithpoly-
merasechainreaction
28andbyhybridcaptureII
29over
a two year interval found similar patterns and similar
associations and risks. In our analysis, however,
women who first had positive results on testing and
then had negative results seemed to have a level of
risk that was similar to those who tested negative
twice, whereas women who tested positive then nega-
tive on hybrid capture II in the study by Kjaëre ta l
29
hadalevelofriskthatwassomewhathigherthanthose
who tested negative twice. We cannot explain the dis-
crepancy between the two reports.
We observed, as have others,
28 that persistence of a
specific HPV genotype predicted a risk of cervical
intraepithelial neoplasia grade II+ only slightly more
strongly than the risk of testing positive twice for the
pool of carcinogenic HPV over a short term interval,
especially at older ages. The greater likelihood of test-
ing positive for carcinogenic HPV because of different
HPV genotypes and persistence of a specific genotype
was greater in women aged <30 than in women aged
≥30, perhaps because more younger women have pre-
valently detected transient infections
30 and are more
likely to clear and then acquire a new infection than
older women. This suggestion is supported by the
Table 4 |Three year and 5 year cumulative incidence rates of cervical intraepithelial neoplasia grade II or more severe (CIN II+) and CIN III+ after repeat
measurements of carcinogenic human papillomavirus (HPV) at about 1 year interval (9-21 months) according to age of women
No of
women
CIN II+ CIN III+
3 year 5 year 3 year 5 year
No of
cases
Rate*
(95% CI)
Rateratio†
(95% CI)
No of
cases
Rate*
(95% CI)
Rateratio†
(95% CI)
No of
cases
Rate*
(95% CI)
No of
cases
Rate*
(95% CI)
Rate ratio†
(95% CI)
Age <30
Carcinogenic HPV
persistence
97 16 19.02 (8.33
to 24.23)
19.40 (2.62
to 143.59)
17 20.29 (11.52
to 29.06)
10.60 (2.51
to 44.70)
8 10.06 (3.31
to 16.82)
9 11.47 (4.28
to 18.65)
12.15 (1.57
to 94.32)
Specific genotype
persistence
66 16 28.22 (16.18
to 40.27)
28.79 (3.91
to 211.99)
17 30.11 (17.83
to 42.40)
15.73 (3.76
to 65.87)
8 15.25 (5.21
to 25.28)
9 17.48 (6.79
to 28.16)
18.53 (2.40
to 143.08)
Non-persistence 31 0 0.00 () 0.00 0 0.00 0.00 0 0.00 0 0.00 0.00
HP 16 persistence 22 11 65.91 (40.36
to 91.46)
67.23 (9.20
to 491.08)
11 65.91 (40.36
to 91.46)
34.43 (8.27
to 143.35)
6 40.34 (11.39
to 69.29)
6 40.34 (11.39
to 69.29)
42.76 (5.35
to 341.78)
HPV 18 persistence 7 1 14.29 (−11.6
to 40.21)
14.57 (1.02
to 209.15)
11 4 . 2 9 ( −11.6
to 40.21)
7.46 (0.77
to 72.62)
0 0.00 0 0.00 0.00
Carcinogenic HPV
persistence
(not 16 and 18)
68 4 7.05 (0.35
to 13.75)
7.19 (0.82
to 62.93)
5 8.77 (1.39
to 16.14)
4.58 (0.92
to 22.91)
23 . 7 7 ( −1.36
to 8.90)
35 . 5 6 ( −0.55
to 11.67)
5.89 (0.63
to 55.28)
Acquisition 56 2 3.57 (−1.29
to 8.43)
3.64 (0.34
to 39.29)
35 . 9 2 ( −0.65
to 12.50)
3.09 (0.53
to 18.08)
11 . 7 9 ( −1.68
to 5.25)
24 . 1 8 ( −1.56
to 9.92)
4.43 (0.41
to 48.15)
Clearance (reference)‡ 125 1 0.98 (−0.93
to 2.89)
1.00 2 1.91 (−0.71
to 4.54)
1.00 0 0.00 1 0.94 (−0.90
to 2.78)
1.00
HPV negative 334 2 0.77 (−0.29
to 1.82)
0.78 (0.07
to 8.53)
20 . 7 7 ( −0.29
to 1.82)
0.40 (0.06
to 2.80)
10 . 3 8 ( −0.37
to 1.13)
10 . 3 8 ( −0.37
to 1.13)
0.41 (0.03
to 6.43)
Age ≥ ≥30
Carcinogenic HPV
persistence
163 22 15.79 (9.69
to 21.89)
11.64 (2.78
to 48.75)
25 25.88 (12.56
to 39.19)
19.07 (4.37
to 83.12)
16 11.84 (6.34
to 17.34)
19 22.40 (8.75
to 36.05)
NA
Specific genotype
persistence
143 22 18.11 (11.21
to 25.02)
13.35 (3.19
to 55.84)
25 30.62 (14.59
to 44.65)
22.56 (5.16
to 98.66)
16 13.67 (7.38
to 19.96)
19 26.85 (10.24
to 43.46)
NA
Non-persistence 20 0 0.00 0.00 0 0.00 0.00 0 0.00 0 0.00 NA
HP 16 persistence 33 8 27.18 (11.09
to 43.26)
20.03 (4.46
to 89.84)
8 27.18 (11.09
to 43.26)
20.03 (4.46
to 89.84)
7 24.67 (8.80
to 40.53)
7 24.67 (8.80
to 40.53)
NA
HPV 18 persistence 11 2 20.45 (−5.14
to 46.05)
15.07 (2.34
to 97.06)
22 0 . 4 5 ( −5.14
to 46.05)
15.07 (2.34
to 97.06)
19 . 0 9 ( −7.90
to 26.08)
19 . 0 9 ( −7.90
to 26.08)
NA
Carcinogenic HPV
persistence (not 16 and
18)
119 12 11.68 (5.42
to 17.93)
8.60 (1.96
to 37.79)
15 23.08 (8.52
to 37.63)
17.01 (3.73
to 77.51)
8 7.87 (2.58
to 13.16)
11 19.77 (4.95
to 34.85)
NA
Acquisition 69 2 3.21 (−1.19
to 7.61)
2.36 (0.34
to 16.54)
23 . 2 1 ( −1.19
to 7.61)
2.36 (0.34
to 16.54)
11 . 4 5 ( −1.37
to 4.27)
11 . 4 5 ( −1.37
to 4.27)
NA
Clearance (reference)‡ 157 2 1.36 (−0.51
to 3.23)
1.00 2 1.36 (−0.51
to 3.23)
1.00 0 0.00 0 0.00 NA
HPV negative 1281 5 0.43 (0.05
to 0.81)
0.32 (0.06
to 1.62)
5 0.43 (0.05
to 0.81)
0.32 (0.06
to 1.62)
30 . 2 6 ( −0.03
to 0.56)
30 . 2 6 ( −0.03
to 0.56)
NA
*Cumulative incidence rates.
†Cumulative incidence rate ratio; when no events of CIN II+ occurred in reference group, this could not be calculated (NA).
‡Women who tested positive and then negative for carcinogenic HPV (“clearance”).
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<30 and ≥30 who tested repeatedly positive for carci-
nogenicHPV butdidnothavepersistence ofa specific
HPV genotype (32.0% v 12.3%).
Strengths and weaknesses
Ourstudyhadseveralstrengths.ThecohortinGuana-
caste was a true population sample, with high partici-
pation rates at enrolment and good rates of follow-up.
There were no obvious biases in follow-up in relation
to the short term HPV status that would invalidate our
findings. Finally, we relied on consensus review of his-
tological end points to reduce misclassification.
There were also several limitations. Firstly, despite
the size of the cohort and subcohort, there were few
outcomes of precancer, resulting in unstable estimates
ofrisk.Thusanylossestofollow-upcouldinfluencethe
absolute estimates of cumulative incidence; however,
asbothHPVinfectionandcervicalintraepithelialneo-
plasia grade II and III are asymptomatic, it is unlikely
thatthereisadifferentialeffectandtherelativepatterns
are unlikely to change significantly. In addition,
because of small numbers of outcomes, in most ana-
lyses we included grade II in our definition of cervical
precancerandcancer.WhilehistologicalgradeIIisthe
typical clinical threshold for treatment, there is an
increasing awareness that it is an equivocal diagnosis
of cervical precancer.
21 Larger studies or pooled data
analyses of existing cohorts, or both, are needed to
more precisely describe these risks of cervical intra-
epithelial neoplasia grade III+ related to short term
persistence.
Secondly, our analysis included only prevalently
detected HPV infections. We did not have enough
cases of cervical intraepithelial neoplasia grade II+
after incident infections to describe the risk after short
term persistence. We therefore cannot apply our find-
ingstodeterminetheutilityofmeasuringpersistenceof
incident infections forrisk stratification. Thisissue will
become important if HPV testing is used in periodic
screeninginthecomingyears.Giventhataproportion
of prevalent infections will have already persisted for
anunknownamountoftime,andthatthelikelihoodof
continued persistence increases with duration of past
persistence,
1213 it is reasonable to expect that monitor-
ing incident infections for more than a year might be
necessary to achieve similar risk stratification as has
been achieved for prevalently detected infections. It
is the duration of persistence—that is, the “age of the
infection”—that predicts progression with specific
HPV genotypes.
13
Thirdly, we needed to make assumptions that com-
pliancewithscheduledclinicvisitswasindependent of
the risk of the end point to justify our statistical
approach. Note that the standard Kaplan-Meier
approach gives estimates of cumulative risk that are
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Fig 3 | Cumulative incidence of cervical intraepithelial neoplasia (CIN) grade II or more severe (grade II+) or grade III+ after
repeat measurements of human papillomavirus (HPV) at about one year interval (9-21 months) in women who had persistent
HPV 16, had persistent HPV 18, tested positive for carcinogenic HPV twice (Pos/Pos), tested positive for carcinogenic HPV at
enrolment but negative at follow-up (“cleared”), tested carcinogenic HPV negative at enrolment but positive at follow-up
(“acquired”), and tested negative at both time points (Neg/Neg). In right panels same groups are stratified by age. Time 0*
indicates start time of analysis, 9-21 months after enrolment
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with an end point have not experienced the end point,
even though here the diagnosis is delayed simply
because they did not appear during the interval for
their visit.
Because of less than perfect sensitivity of
colposcopy,
31 we cannot truly distinguish between
missed prevalent and incident disease, nor can we
separate missed miniscule foci of prevalent disease
ensuring viral persistence versus viral persistence pre-
dicting the progression to cervical intraepithelial neo-
plasia grade II+. Many histologically confirmed cases
of grade II+ (n=144) were diagnosed during the enrol-
ment phase. It seems likely that some cases detected
duringfollow-upundoubtedlywerepresentbutmissed
by enrolment colposcopy, just as in routine clinical
practice. The purpose of our analysis, however, was
to describe the risk of having or developing cervical
intraepithelial neoplasia grade II+ after patterns of
HPV detection and to determine the best format of
detection with HPV genotyping rather than making
any distinctions about the “origins” of the viral persis-
tence or cervical intraepithelial neoplasia grade II+.
Clinical implications
MonitoringofprevalentlydetectedHPVinfectionsfor
short term persistence might be useful for identifying
the women positive for carcinogenic HPV at risk of
cervical intraepithelial neoplasia grade II+ in the fol-
lowing years.
Table 5 |Three year and 5 year cumulative incidence rates of cervical intraepithelial neoplasia grade II or more severe (CIN II+) and CIN III+ after repeat
measurements of carcinogenic human papillomavirus (HPV) at about 1 year interval (9-21 months) according to cytology results
No of
women
CIN II+ CIN III+
3 year 5 year 3 year 5 year
No of
cases
Rate*
(95% CI)
Rate ratio†
(95% CI)
No of
cases
Rate*
(95% CI)
Rate ratio†
(95% CI)
No of
cases
Rate*
(95% CI)
No of
cases
Rate*
(95% CI)
Rate ratio†
(95%CI)
ASCUS or more severe cytology
Carcinogenic HPV
persistence
89 21 28.79(18.12
to 39.46)
NA 21 28.79 (18.12
to 39.46)
NA 11 15.00 (6.53
to 23.48)
11 15.00 (6.53
to 23.48)
NA
Specific genotype
persistence
73 21 34.93(22.49
to 47.36)
NA 21 34.93 (22.49
to 47.36)
NA 11 18.73 (8.25
to 29.20)
11 18.73 (8.25
to 29.20)
NA
Non-persistence 16 0 0.00 NA 0 0.00 NA 0 0.00 0 0.00 NA
HP 16 persistence 17 8 58.18(30.88
to 85.48)
NA 8 58.18 (30.88
to 85.48)
NA 4 27.94 (3.29
to 52.59)
4 27.94 (3.29
to 52.59)
NA
HPV 18 persistence 9 3 37.78 (2.91
to 72.65)
NA 3 37.78 (2.91
to 72.65)
NA 1 11.11 (−9.42
to 31.64)
1 11.11 (−9.42
to 31.64)
NA
Carcinogenic HPV
persistence (not 16
and 18)
63 10 19.62 (8.51
to 30.73)
NA 10 19.62 (8.51
to 30.73)
NA 6 11.80 (2.71
to 20.90)
6 11.80 (2.71
to 20.90)
NA
Acquisition 31 1 3.23 (−2.99
to 9.45)
NA 1 3.23 (−2.99
to 9.45)
NA 1 3.23 (−2.99
to 9.45)
13 . 2 3 ( −2.99
to 9.45)
NA
Clearance
(reference)‡
30 0 0.00 NA 0 0.00 NA 0 0.00 0 0.00 NA
HPV negative 115 3 2.86 (−0.36
to 6.07)
NA 3 2.86 (−0.36
to 6.07)
NA 2 2.00 (−2.00
to 4.76)
22 . 0 0 ( −2.00
to 4.76)
NA
Negative cytology
Carcinogenic HPV
persistence
162 16 11.47 (6.15
to 16.79)
8.24 (2.44
to 27.83)
20 23.22 (9.00
to 37.44)
12.38 (3.92
to 39.06)
12 9.12 (4.19
to 14.05)
16 21.18 (6.72
to 35.64)
43.21 (5.45
to 342.72)
Specific genotype
persistence
129 16 14.50 (7.89
to 21.10)
8.29 (2.40
to 28.59)
20 28.86 (11.91
to 44.80)
15.11 (4.87
to 46.90)
12 11.61 (5.42
to 17.80)
16 25.94 (9.11
to 42.77)
52.92 (6.74
to 415.20)
Non-persistence 33 0 0.00 0.00 0 0.00 0.00 0 0.00 0 0.00 0.00
HP 16 persistence 36 10 32.76(15.92
to 49.60)
23.52 (6.82
to 81.1)
10 32.76 (15.92
to 49.60)
17.46 (5.81
to 52.45)
8 28.80 (11.89
to 45.72)
8 28.80 (11.89
to 45.72)
58.76 (7.63
to 452.57)
HPV 18 persistence 9 0 0.00 0.00 0 0.00 0.00 0 0.00 0 0.00 0.00
Carcinogenic HPV
persistence
(not 16 and 18)
117 6 5.91 (1.31
to 10.51)
4.25 (1.08
to 16.68)
10 20.25 (3.76
to 36.74)
10.79 (3.04
to 38.37)
4 4.08 (0.16
to 8.00)
8 18.70 (2.03
to 35.36)
38.14 (4.45
to 327.05)
Acquisition 88 3 3.69 (−0.44
to 7.81)
2.65 (0.54
to 12.95)
4 5.01 (0.20
to 9.82)
2.67 (0.68
to 10.47)
11 . 1 4 ( −1.08
to 3.35)
12 . 4 9 ( −0.93
to 5.91)
5.08 (0.47
to 55.45)
Clearance
(reference)‡
236 3 1.39 (−0.18
to 2.96)
1.00 4 1.88 (0.05
to 3.70)
1.00 0 0.00 1 0.49 (−0.47
to 1.45)
1.00
HPV negative 1449 4 0.32 (0.01
to 0.64)
0.23 (0.05
to 1.03)
4 0.32 (0.01
to 0.64)
0.17 (0.04
to 0.68)
20 . 1 6 ( −0.06
to 0.39)
20 . 1 6 ( −0.06
to 0.39)
0.33 (0.03
to 3.63)
ASCUS=atypical squamous cells of undetermined significance.
*Cumulative incidence rates.
†Cumulative incidence rate ratio; when no events of CIN II+ occurred in reference group, this could not be calculated (NA).
‡Women who tested positive and then negative for carcinogenic HPV (“clearance”).
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clinically useful monitoring of HPV 16 and perhaps
HPV 18, beginning at age 25 when the risk of precan-
cer becomes non-trivial. For women between the ages
of25-30,itwillbeespeciallyimportantforcliniciansto
wait for evidence of persistence rather than act on the
first positive test for HPV 16 and 18. It is less clear
whetherthereisclinicalutilityfordetectingpersistence
of a specific HPV genotype among those repeatedly
positive for carcinogenic HPV genotypes other than
HPV 16 and 18. Specifically monitoring the other car-
cinogenic HPV genotypes does differentiate women
with persistent specific HPV infections who are at
risk of cervical intraepithelial neoplasia grade II+
from those who test positive for different HPV geno-
typesandarenotatriskofgradeII+.Mostwomenwho
tested repeatedly positive for carcinogenic HPV had
viral persistence, although less so for women under
30.Asaconsequence,detectionofpersistenceofaspe-
cific HPV genotype of other carcinogenic genotypes
did not provide significant risk stratification above
that achieved by pooled detection of all other carcino-
genic genotypes. Thus, it might be more practical to
specifically monitor only the riskiest HPV genotypes,
such as HPV 16 and 18, and detect the other carcino-
genic genotypes in aggregate, accepting the trade-off
thatafractionofrepeatpositivesforothercarcinogenic
genotypes do not represent HPV persistence in
exchange for greater reliability for detecting those
thatdo.Furtherevaluationofthesetrade-offsandaccu-
racyversuseaseofuse,
32withconsiderationofanycost
differences, is warranted.
Table 6 |Three year and 5 year cumulative incidence rates of cervical intraepithelial neoplasia grade II or more severe (CIN II+) and CIN III+ after repeat
measurements of carcinogenic human papillomavirus (HPV) at about 1 year interval (9-21 months) according to whether women underwent colposcopy
during time interval
No of
women
CIN II+ CIN III+
3 year 5 year 3 year 5 year
No of
cases
Rate*
(95% CI)
Rateratio†
(95% CI)
No of
cases
Rate*
(95% CI)
Rateratio†
(95% CI)
No of
cases
Rate*
(95% CI)
No of
cases
Rate*
(95% CI)
Rate ratio†
(95% CI)
Colposcopy
Carcinogenic HPV
persistence
144 27 21.56 (14.28
to 28.84)
11.31 (3.50
to 36.54)
28 22.48 (15.07
to 29.89)
11.80 (3.66
to 38.02)
17 14.37 (7.97
to 20.78)
18 15.38 (8.75
to 22.01)
NA
Specific genotype
persistence
115 27 27.14 (18.28
to 35.99)
14.24 (4.42
to 45.85)
28 28.35 (19.33
to 37.38)
14.88 (4.63
to 47.79)
17 18.38 (10.34
to 26.41)
18 19.74 (11.40
to 28.07)
NA
Non-persistence 29 0 0.00 0.00 0 0.00 0.00 0 0.00 0 0.00 NA
HP 16 persistence 35 11 37.45 (19.58
to 55.33)
19.65 (5.80
to 66.58)
11 37.45 (19.58
to 55.33)
19.65 (5.80
to 66.58)
7 26.79 (9.38
to 44.20)
7 26.79 (9.38
to 44.20)
NA
HPV 18 persistence 11 3 27.27 (0.95
to 53.59)
14.31 (3.26
to 62.90)
3 27.27 (0.95
to 53.59)
14.31 (3.26
to 62.90)
19 . 0 9 ( −7.90
to 26.08)
19 . 0 9 ( −7.90
to 26.08)
NA
Carcinogenic HPV
persistence (not 16 and
18)
98 13 15.55 (7.73
to 23.36)
8.16 (2.38
to 27.91)
14 16.87 (8.76
to 24.97)
8.85 (2.61
to 30.02)
9 11.00 (4.17
to 17.82)
10 12.39 (5.15
to 19.63)
NA
Acquisition 79 2 2.53 (−0.93
to 6.00)
1.33 (0.23
to 7.80)
34 . 1 6 ( −0.49
to 8.80)
2.18 (0.45
to 10.63)
22 . 5 3 ( −0.93
to 6.00)
34 . 1 6 ( −0.49
to 8.80)
NA
Clearance (reference)‡ 170 3 1.91 (−0.23
to 4.05)
1.00 3 1.91 (−0.23
to 4.05)
1.00 0 0.00 0 0.00 NA
HPV negative 985 5 0.58 (0.07
to 1.09)
0.30 (0.07
to 1.26)
5 0.58 (0.07
to 1.09)
0.30 (0.07
to 1.26)
4 0.46 (0.01
to 0.91)
4 0.46 (0.01
to 0.91)
NA
No colposcopy
Carcinogenic HPV
persistence
116 11 11.14 (4.85
to 17.42)
NA 14 25.73 (7.64
to 43.81)
25.21 (3.17
to 200.37)
7 7.30 (2.02
to 12.57)
10 22.51 (3.93
to 41.10)
22.06 (2.65
to 183.37)
Specific genotype
persistence
94 11 13.79 (6.11
to 21.46)
NA 14 33.98 (10.10
to 57.86)
33.30 7 9.13 (2.58
to 15.67)
10 30.41 (5.50
to 55.31)
29.80 (3.59
to 247.02)
Non-persistence 22 0 0.00 NA 0 0.00 0.00 0 0.00 0 0.00 0.00
HPV 16 persistence 20 8 45.36 (21.77
to 68.94)
NA 8 45.36 (21.77
to 68.94)
44.45 (5.91
to 334.45)
6 35.71 (12.44
to 58.99)
6 35.71 (12.44
to 58.99)
35.00 (4.48
to 273.52)
HPV 18 persistence 7 0 0.00 NA 0 0.00 0.00 0 0.00 0 0.00 0.00
Carcinogenic HPV
persistence
(not 16 and 18)
89 3 3.66 (−0.44
to 7.76)
NA 6 20.92 (0.49
to 41.34)
20.50 (2.32
to 181.49)
11 . 1 2 ( −1.07
to 3.31)
41 8 . 8 3 ( −1.92
to 39.59)
18.46 (1.97
to 173.34)
Acquisition 46 2 4.97 (−1.01
to 11.74)
NA 2 4.97 (−1.01
to 11.74)
4.87 (0.45
to 52.59)
0 0.00 0 0.00 0.00
Clearance (reference)† 112 0 0.00 NA 1 1.02 (−0.97
to 3.01)
1.00 0 0.00 1 1.02 (−0.97 to
3.01)
1.00
HPV negative 630 2 0.35 (−0.14
to 0.83)
NA 2 0.35 (−0.14
to 0.83)
0.34 (0.03
to 3.75)
0 0.00 0 0.00 0.00
*Cumulative incidence rates.
†Cumulative incidence rate ratio; when no events of CIN II+ occurred in reference group, this could not be calculated (NA).
‡Women who tested positive and then negative for carcinogenic HPV (“clearance”).
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